目的 探讨脑脉泰胶囊联合丁苯酞软胶囊治疗急性脑梗死的临床疗效。方法 选取2019年8月—2020年11月在天津市宁河区医院就诊的92例急性脑梗死患者，按照随机数字表将所有患者分为对照组和治疗组，每组各46例。对照组口服丁苯酞软胶囊，0.2 g/次，3次/d。治疗组在对照组患者治疗的基础上口服脑脉泰胶囊，2粒/次，3次/d。两组患者连续治疗1个月。观察两组的临床疗效，比较两组的血流动力学指标、血清因子水平、神经功能缺损程度。结果 治疗后，治疗组的总有效率为95.65%，对照组的总有效率为82.61%，组间比较差异有统计学意义（P<0.05）。治疗后，两组的平均流速（V_m）、最小血流量（Q_min）明显升高，阻力指数（RI）明显降低（P<0.05）；治疗后，治疗组的V_m、Q_min高于对照组，RI低于对照组，差异有统计学意义（P<0.05）。治疗后，两组的内皮素-1（ET-1）、血管紧张素Ⅱ（Ang Ⅱ）、白细胞介素-17（IL-17）水平均明显降低（P<0.05）；治疗组的ET-1、Ang Ⅱ、IL-17水平低于对照组（P<0.05）。治疗后，两组的美国国立卫生研究院卒中量表（NIHSS）评分明显降低（P<0.05），治疗组NIHSS评分降低更明显，差异有统计学意义（P<0.05）。结论 脑脉泰胶囊联合丁苯酞软胶囊可提高急性脑梗死的临床疗效，有助于改善血流动力学和血管内皮功能，减轻神经功能缺损程度。

Objective To investigate the clinical efficacy of Naomaitai Capsules combined with Butylphthalide Soft Capsules in treatment of acute cerebral infarction. Methods Patients (92 cases) with acute cerebral infarction in Tianjin Ninghe Hospital from August 2019 to November 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Butylphthalide Soft Capsules, 0.2 g/time, three times daily. Patients in the treatment group were po administered with Naomaitai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and hemodynamic parameters, serum factor levels, and neurological deficit in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.65%, the total effective rate of the control group was 82.61%, and the difference was statistically significant (P<0.05). After treatment, the V_m and Q_min of two groups were significantly increased, but the RI of two groups was significantly decreased (P<0.05). After treatment, the V_m and Q_min of the treatment group were higher than those of the control group, but the RI of the treatment group was lower than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of ET-1, Ang Ⅱ, and IL-17 in two groups were significantly decreased treatment, the NIHSS score of two groups were significantly decreased (P<0.05), and the NIHSS score of the treatment group was significantly lower than that of the control group, the difference was statistically significant (P<0.05). (P<0.05), but the levels of ET-1, Ang Ⅱ, and IL-17 in the treatment group were lower than those in the control group (P<0.05). After Conclusion Naomaitai Capsule combined with Butylphthalide Soft Capsules can improve the clinical effect of acute cerebral infarction, improve hemodynamics and vascular endothelial function, reduce the degree of nerve function defects.

R971

天津市自然科学基金资助项目（SJCYBJC27800）